

COMBINED DECLARATION AND POWER OF ATTORNEY

(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL, DIVISIONAL,
CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a(n) original application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

**METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-RELATED DISORDERS
USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397,
13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 OR 46777**

SPECIFICATION IDENTIFICATION

The specification was filed on February 27, 2004, as U.S. Application Serial No. 10/789,241.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56, and which is material to the examination of this application, namely, information where there is a substantial likelihood that a reasonable Examiner would consider it important in deciding whether to allow the application to issue as a patent.

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)
UNDER 35 U.S.C. SECTION 119 or 35 U.S.C. SECTION 365**

I hereby claim the benefit, under Title 35, United States Code, Section 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or Title 35, United States Code, Section 365(a) of any PCT international application which designated at least one country other than the United States of America, and have also identified below, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATIONS OR U.S. PROVISIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. SECTION 119:				
FOREIGN APPLICATION NO.	FILING DATE	Country	Priority Claimed	Status

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

PROVISIONAL APPLICATION NO.	FILING DATE			
60/454,202	3/12/2003			
60/456,326	3/20/2003			
60/465,240	4/24/2003			
60/475,233	6/2/2003			
60/478,952	6/16/2003			
60/487,836	7/16/2003			
60/500,111	9/4/2003			

**CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)
UNDER 35 U.S.C. SECTION 120**

I hereby claim the benefit, under Title 35, United States Code, Section 120, of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed

Practitioner's Docket No. MPI03-041P1RNOMNIM

below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information that occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application.

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. SECTION 120:				
U.S. APPLICATIONS		Status		
U.S. APPLICATIONS	U.S. FILING DATE	Patented	Pending	Abandoned
PCT APPLICATION DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. APPLICATION NOS. ASSIGNED (IF ANY)		

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)	REGISTRATION NUMBER(S)
Scott A. Brown	32,724
Ian R. Silverman	37,443
Jean M. Silveri	39,030
Allan N. Kutzenco	38,945
Janice M. Klunder	41,121
Kerri Pollard Schray	47,066
Tracy M. Sioussat	50,609

Practitioner's Docket No. MPI03-041P1RNOMNIM

DIRECT ALL CORRESPONDENCE TO:
CUSTOMER NUMBER 30405

OR

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

Jean M. Silveri
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139

Jean M. Silveri
(617) 679-7336

DIRECT FACSIMILE CORRESPONDENCE TO:

Jean M. Silveri
(617) 551-8820

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Powell, Douglas M.
Inventor's signature

Douglas Powell

Date

3/22/04

Residence 62 Grist Mill Road, Littleton, Massachusetts 01460

Post Office Address 62 Grist Mill Road, Littleton, Massachusetts 01460

Country of Citizenship United States

JANICE A. DILLON
Notary Public
My Commission Expires
8/9/2007

Janice A. Dillon



Practitioner's Docket No. **MPI03-041P1RNOMNIM**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Powell, Douglas M.
Application No.: 10/789,241 Group No.: 1645
Filed: February 27, 2004 Examiner: TBA
For: METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-RELATED DISORDERS USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982 OR 46777

**Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

ASSOCIATE POWER OF ATTORNEY

Dear Sir:

The undersigned attorney has the power of attorney in the subject application. She hereby grants an associate power to:

Mario Cloutier
Millennium Pharmaceuticals, Inc.
40 Landsdowne Street
Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____
- ☐ transmitted by facsimile to the Patent and Trademark Office.

TRANSMISSION

Signature

Diana Gentile

(type or print name of person certifying)

Date: May 7, 2004

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

As demonstrated by Appendix A (submitted herewith), Mario Cloutier has passed the Patent Bar Examination and has been granted limited recognition under 37 C.F.R. §10.9(b). Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.


Entry of the remarks made herein is respectfully requested.

May 7, 2004

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Jean M. Silveri

Registration No. 39,030

40 Landsdowne Street

Cambridge, MA 02139

Telephone – (617) 679-7336

Facsimile – (617) 551-8820

**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

A handwritten signature in black ink, appearing to read "Harry I. Moatz", is written over a horizontal line.

**Harry I. Moatz
Director of Enrollment and Discipline**



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

**Harry I. Moatz
Director of Enrollment and Discipline**